dapagliflozin - Profile

What are the generic drug sources for dapagliflozin and what is the scope of freedom to operate?

Dapagliflozin is the generic ingredient in four branded drugs marketed by Astrazeneca Ab and is included in four NDAs. There are eighteen patents protecting this compound. Additional information is available in the individual branded drug profile pages.

Dapagliflozin has four hundred and twenty-three patent family members in fifty-two countries.

There are nineteen tentative approvals for this compound.

Summary for dapagliflozin

International Patents:	423
US Patents:	18
Tradenames:	4
Applicants:	1
NDAs:	4
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for dapagliflozin

DrugPatentWatch^® Estimated Loss of Exclusivity (LOE) Date for dapagliflozin

Dosage:

TABLET;ORAL

^*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

Generic filers with tentative approvals for DAPAGLIFLOZIN

Applicant	Application No.	Strength	Dosage Form
		2.5MG;1GM	TABLET, EXTENDED RELEASE;ORAL
		10MG;1GM	TABLET, EXTENDED RELEASE;ORAL
		10MG;500MG	TABLET, EXTENDED RELEASE;ORAL

The 'tentative' approval signifies that the product meets all FDA standards for marketing, and, but for the patents / regulatory protections, it would approved.

Paragraph IV (Patent) Challenges for DAPAGLIFLOZIN

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
FARXIGA	Tablets	dapagliflozin	5 mg and 10 mg	202293	20	2018-01-08

US Patents and Regulatory Information for dapagliflozin

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Astrazeneca Ab	FARXIGA	dapagliflozin	TABLET;ORAL	202293-001	Jan 8, 2014		RX	Yes	No					Y
Astrazeneca Ab	FARXIGA	dapagliflozin	TABLET;ORAL	202293-001	Jan 8, 2014		RX	Yes	No					Y
Astrazeneca Ab	FARXIGA	dapagliflozin	TABLET;ORAL	202293-001	Jan 8, 2014		RX	Yes	No					Y

Expired US Patents for dapagliflozin

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Astrazeneca Ab	FARXIGA	dapagliflozin	TABLET;ORAL	202293-002	Jan 8, 2014
Astrazeneca Ab	FARXIGA	dapagliflozin	TABLET;ORAL	202293-001	Jan 8, 2014
Astrazeneca Ab	FARXIGA	dapagliflozin	TABLET;ORAL	202293-002	Jan 8, 2014

EU/EMA Drug Approvals for dapagliflozin

Company	Drugname	Inn	Product Number / Indication	Status	Generic	Biosimilar	Orphan	Marketing Authorisation	Marketing Refusal
AstraZeneca AB	Forxiga	dapagliflozin	EMEA/H/C/002322Type 2 diabetes mellitusForxiga is indicated in adults and children aged 10 years and above for the treatment of insufficiently controlled type 2 diabetes mellitus as an adjunct to diet and exerciseas monotherapy when metformin is considered inappropriate due to intolerance.in addition to other medicinal products for the treatment of type 2 diabetes.For study results with respect to combination of therapies, effects on glycaemic control, cardiovascular and renal events, and the populations studied, see sections 4.4, 4.5 and 5.1.Heart failureForxiga is indicated in adults for the treatment of symptomatic chronic heart failure.Chronic kidney diseaseForxiga is indicated in adults for the treatment of chronic kidney disease.	Authorised	no	no	no	2012-11-11
AstraZeneca AB	Edistride	dapagliflozin	EMEA/H/C/004161Type 2 diabetes mellitusEdistride is indicated in adults and children aged 10 years and above for the treatment of insufficiently controlled type 2 diabetes mellitus as an adjunct to diet and exerciseas monotherapy when metformin is considered inappropriate due to intolerance.in addition to other medicinal products for the treatment of type 2 diabetes.For study results with respect to combination of therapies, effects on glycaemic control, cardiovascular and renal events, and the populations studied, see sections 4.4, 4.5 and 5.1.Heart failureEdistride is indicated in adults for the treatment of symptomatic chronic heart failure.Chronic kidney diseaseEdistride is indicated in adults for the treatment of chronic kidney disease.	Authorised	no	no	no	2015-11-09
Viatris Limited	Dapagliflozin Viatris	dapagliflozin	EMEA/H/C/006006Type 2 diabetes mellitusDapagliflozin Viatris is indicated in adults and children aged 10 years and above for the treatment of insufficiently controlled type 2 diabetes mellitus as an adjunct to diet and exercise- as monotherapy when metformin is considered inappropriate due to intolerance.- in addition to other medicinal products for the treatment of type 2 diabetes.For study results with respect to combination of therapies, effects on glycaemic control, cardiovascular and renal events, and the populations studied, see sections 4.4, 4.5 and 5.1.Heart failureDapagliflozin Viatris is indicated in adults for the treatment of symptomatic chronic heart failure with reduced ejection fraction.Chronic kidney diseaseDapagliflozin Viatris is indicated in adults for the treatment of chronic kidney disease.	Authorised	yes	no	no	2023-03-24

International Patents for dapagliflozin

Country	Patent Number	Title	Estimated Expiration
World Intellectual Property Organization (WIPO)	2022022865
Israel	319642	שיטות לטיפול ב hfpef בשימוש דאפאגליפלוזין ותרכובות המכילות אותה (Methods of treating hfpef employing dapagliflozin and compositions comprising the same)
Portugal	2139494

Supplementary Protection Certificates for dapagliflozin

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
2139494	SPC/GB20/028	United Kingdom		PRODUCT NAME: SAXAGLIPTIN AND DAPAGLIFLOZIN; REGISTERED: UK EU/1/16/1108 (NI) 20160719; UK PLGB 17901/0339 20160719
1506211	CA 2014 00037	Denmark		PRODUCT NAME: ET KOMBINATIONSPRODUKT AF DAPAGLIFLOZIN ELLER ET FARMACEUTISK ACCEPTABELT SALT DERAF, HERUNDER DAPAGLIFLOZINPROPANDIOLMONOHYDRAT OG METFORMIN ELLER SALTE DERAF, HERUNDER METFORMINHYDROCHLORID; REG. NO/DATE: EU/1/13/900 20140116
2498758	CR 2020 00017	Denmark		PRODUCT NAME: METFORMIN ELLER ET FARMACEUTISK ACCEPTABELT SALT DERAF; SAXAGLIPTIN ELLER ET FARMACEUTISK ACCEPTABELT SALT DERAF; DAPAGLIFLOZIN ELLER ET FARMACEUTISK ACCEPTABELT SOLVAT DERAF; REG. NO/DATE: EU/1/19/1401 20191113

Dapagliflozin: Investment Scenario, Market Dynamics, and Financial Trajectory

Last updated: February 3, 2026

---

Summary

Dapagliflozin, marketed under brand names such as Farxiga and Forxiga, is a sodium-glucose co-transporter 2 (SGLT2) inhibitor primarily approved for treating type 2 diabetes mellitus (T2DM). As a pioneering SGLT2 inhibitor, dapagliflozin has expanded indications, including heart failure and chronic kidney disease, positioning it as a significant asset within the broader cardiovascular and renal therapeutic markets.

This analysis explores the current market landscape, projected growth trajectories, competitive dynamics, and investment considerations associated with dapagliflozin. The insights focus on its revenue potential, R&D pipeline, regulatory environment, and competitive positioning, offering a comprehensive understanding for investors and stakeholders.

---

1. Market Overview and Current Revenue Landscape

1.1. Market Size and Penetration (2023)

Parameter	Data	Sources
Global T2DM market (2023)	$96.5 billion	[1]
SGLT2 inhibitors share	Approx. 23%	[2]
Dapagliflozin's global sales (2022)	~$4.1 billion	[3]
Key approved indications	T2DM, Heart Failure, Chronic Kidney Disease	[4]

1.2. Leading Market Players & Market Share

Company	Product	Revenue (2022)	Share of Total SGLT2 Market	Notes
AstraZeneca	Farxiga/Forxiga	~$4.1 billion	~67%	Market leader
Lilly/Boehringer	Jardiance (empagliflozin)	~$2.5 billion	~41%	Main competitor
Others	Invokana (canagliflozin), etc.	N/A	~20%	Smaller share

Note: Market shares are approximate and based on multiple industry sources and IQVIA reports.

---

2. Market Dynamics Influencing Dapagliflozin

2.1. Expanding Approved Indications

Dapagliflozin's expanded indications in recent years are catalyzing its growth:

• Heart Failure with Reduced Ejection Fraction (HFrEF): Approved in the US (2020) and EU (2021).
• Chronic Kidney Disease (CKD): Approved in the US (2021).

This diversification limits dependency on T2DM sales alone, broadening revenue streams.

2.2. Regulatory Environment & Approvals

Region	Key Approvals	Recent Updates	Regulatory Challenges
US	Multiple indications, including HFrEF and CKD (FDA 2020/2021)	Expanded label	Post-approval surveillance
EU	Similar approvals	Sequential approvals	Adaptation to regional policies
China & Asia	Rapid uptake, approval for T2DM	Growing markets	Pricing and reimbursement hurdles

2.3. Competitive Landscape & Market Share Shifts

Competitor	Primary Drug	Revenue (2022)	Market Position	Differentiators
AstraZeneca	Farxiga	$4.1B	Leader	Broad indications, early approvals
Lilly/Boehringer	Jardiance	$2.5B	Second place	Strong cardiovascular data
Pfizer/Johnson & Johnson	Invokana	N/A	Smaller	First-in-class, prior approvals

Market share is shifting towards drugs with broader indications and favorable trial outcomes.

2.4. Pricing & Reimbursement Trends

• Price erosion due to biosimilar entry as patent expirations approach in select markets.
• Reimbursement policies increasingly favor SGLT2 inhibitors for CKD and HF indications, improving market access.

---

3. Financial Trajectory and Revenue Forecasts

3.1. Short-term (2023-2025) Projections

Parameter	2023	2024	2025	Notes
Sales	~$4.1B	$4.5B	$5.0B	Growth driven by expanded indications and market penetration
Growth Rate	8.5%	10%	11.1%	CAGR based on historical trends and pipeline data
R&D Investment	~$300 million annually			Focus on pipeline expansion

3.2. Long-term (2026-2030) Outlook

Parameter	2026	2028	2030	Notes
Revenue	~$5.5B	~$7.2B	~$9.0B	Driven by new indications and global expansion
Market share	~30%			Assumes continued leadership position

These projections consider potential patent cliffs, generic entry, and approval of next-generation SGLT2 inhibitors.

3.3. Key Revenue Drivers

• Geographic expansion: Growth in emerging markets like China and India.
• Indication expansion: Continued approval for additional heart failure and CKD indications.
• Combination therapies: Partnerships with other drug developers for combination regimens.

---

4. Investment Considerations and Risks

Factors	Impact	Mitigation Strategies
Patent expiration	Revenue erosion	Active pipeline, new indications
Competition	Market share dilution	Differentiation, label expansion
Regulatory delays	Market entry setbacks	Strategic early engagement
Pricing pressures	Margins squeezed	Cost optimization, value-based pricing

---

5. Competitive Differentiation and R&D Investment

5.1. Pipeline Overview

Candidate	Indication	Stage	Expected Launch	Differentiation
Dapagliflozin Next-gen	Cardiometabolic	Phase III	2025–2027	Improved efficacy, safety profile
Combination therapies	T2DM, HF	Preclinical	2026+	Synergistic effects

5.2. Strategic Partnerships

• Collaborations with biotech firms for novel formulations.
• Licensing agreements to extend indications beyond metabolic diseases.

---

6. Comparative Analysis: Dapagliflozin Versus Peers

Feature	Dapagliflozin	Jardiance (Empagliflozin)	Invokana (Canagliflozin)
Approved Indications	T2DM, HFrEF, CKD	T2DM, CV mortality	T2DM, Renal and CV benefits
Patent Expiry	~2028	~2028	~2025
Sales (2022)	~$4.1B	~$2.5B	N/A
Key Differentiators	Broad indications	Strong CV outcomes	First-in-class

---

7. Market Entry and Regulatory Pathways

7.1. Accelerated Approval Routes

• Breakthrough Therapy Designation.
• Priority Review in key markets.

7.2. Challenges in Entry

• Stringent safety data requirements due to adverse events (e.g., ketoacidosis).
• Price negotiations and reimbursement hurdles.

---

8. Key Performance Indicators (KPIs) for Stakeholders

Metric	Benchmark	Relevance
Revenue Growth	CAGR of >10% (2023-2030)	Financial health
Market Share	Maintaining >30%	Competitive positioning
R&D Spend as % of Revenue	~7-10%	Innovation pipeline health
Approval Rate for New Indications	>80% success	Expansion potential

---

Key Takeaways

• Strong Market Position: Dapagliflozin leads the SGLT2 inhibitor class, with expanding indications bolstering revenue streams.
• Growth Prospects: Revenue is projected to grow at an 8-11% CAGR through 2030, driven by indication expansion and global reach.
• Competitive Edge: Differentiators include broader approvals, strategic partnerships, and a robust pipeline.
• Risks: Patent cliffs, increasing competition, and regulatory hurdles require proactive management.
• Investment Opportunity: Continued innovation, geographic expansion, and lifecycle management make dapagliflozin a compelling long-term asset.

---

FAQs

Q1: How soon could generic versions of dapagliflozin impact its revenue?
Predicted around 2028, aligning with patent expiration in key markets, unless patent extensions or exclusivity periods are secured.

Q2: What are the main drivers for dapagliflozin's growth beyond T2DM?
Its approvals for heart failure and CKD significantly diversify revenue streams, capturing broader patient populations.

Q3: How does dapagliflozin compare to Jardiance in clinical outcomes?
Both have demonstrated cardiovascular and renal benefits, with some studies suggesting marginal differences; regulatory labels may influence prescribing patterns.

Q4: What are key regulatory hurdles for future approvals?
Demonstrating safety in broader indications and managing adverse events such as euglycemic ketoacidosis are primary challenges.

Q5: What impact could biosimilars have on dapagliflozin's market?
While biosimilars are less relevant for small molecule drugs like dapagliflozin, generic manufacturing could exert pricing pressures post-patent expiry.

---

References

[1] Grand View Research, "Global Type 2 Diabetes Mellitus Market Size & Trends," 2023.
[2] IQVIA, "Global Market Data," 2023.
[3] AstraZeneca Financial Reports, 2022.
[4] FDA Approvals Database, 2021-2023.
[5] Evaluate Pharma, "SGLT2 Inhibitors Market Analysis," 2023.

---

This detailed review provides strategic insights into dapagliflozin’s financial and market trajectory, enabling informed decision-making for investors and healthcare stakeholders.